Nonsegmental Vitiligo

Nonsegmental Vitiligo Trial

Trial ID: NCT06113445

Phase 3 | Oral tablet | 52 week treatment period

• ≥ 18 years old
• Must have Vitiligo affecting both face body body with the disease affecting > 10% of the body surface area with scores of ≥ 0.5 and 5 for both face and body respectively
• Candidate for systemic therapy
• Good general health

Exclusion Criteria:

• A washout period is mandatory for participants using biologics, JAK inhibitors, immunosuppressants, or undergoing phototherapy
• Other forms of vitiligo or skin depigmentation

Nonsegmental Vitiligo Trial

Trial ID: NCT06118411

Phase 3 | Oral tablet | 48-112 week treatment period

• ≥ 12 years old and weigh ≥ 30 kg
• Must have a history Vitiligo affecting both face and body
• Body surface area disease affects should be between 10% and 50%
• Actively progressing vitiligo or a history of failing ≥ 1 topical corticosteroid and/or calcineurin inhibitor treatment
• Good general health

Exclusion Criteria:

• Prior use of a JAK inhibitor or permanent bleaching agents
• A washout period is mandatory for participants using biologics or undergoing phototherapy